Ethambutol Optic Neuropathy: Vigilance and Screening, the Keys to Prevent Blindness with the Revised Anti-tuberculous Therapy Regimen
There has been change in the guidelines for the management of tuberculosis in India. The new guidelines advocate the daily use of Ethambutol for both intensive and continuation phase of the treatment. This may be a matter of concern as increased cumulative dose may lead to increase in incidence of t...
Gespeichert in:
| Veröffentlicht in: | Journal of the Association of Physicians of India 2021-02, Vol.69 (2), p.54 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 54 |
| container_title | Journal of the Association of Physicians of India |
| container_volume | 69 |
| creator | Saxena, Rohit Phuljhele, Swati Prakash, Anupam Lodha, Rakesh Singh, Digvijay Karna, Satya Mohan, Anant Gandhi, Rashmin Menon, Vimla Garg, Rajiv The Inosrg |
| description | There has been change in the guidelines for the management of tuberculosis in India. The new guidelines advocate the daily use of Ethambutol for both intensive and continuation phase of the treatment. This may be a matter of concern as increased cumulative dose may lead to increase in incidence of toxic optic neuropathy due to ethambutol. Indian Neuro-Ophthalmology Society has taken cognizance of the issue and has come-up with guidelines for prevention and early detection of the toxic optic neuropathy. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_33527812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33527812</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-87d3c4742951d43c80775ca5be1c63ace08eac7336b25b7265a0996c3f5eafbd3</originalsourceid><addsrcrecordid>eNo1kEtOwzAUAL0A0VK4AvIBiOTYcZywK1X5iIoiKGwrf14So8SJbKcoB-DeID6r2YxmMUdoTgjJEi4EnaHTEN4JYSVj9ATNGONUFCmdo891bGSnxti3eDtEq_EjjL4fZGymK_xma9tKpwFLZ_CL9gDOuvoSxwbwA0wBxx4_eTiAi_i6tc44CAF_2Nj8KM9wsAEMXrpokzgq8Hps-zHgXQNeDtO3UNsO3Bk6rmQb4PyPC_R6s96t7pLN9vZ-tdwkQ0rzmBTCMJ2JjJY8NRnTBRGCa8kVpDpnUgMpQGrBWK4oV4LmXJKyzDWrOMhKGbZAF7_dYVQdmP3gbSf9tP__wb4Aqkxdzg</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ethambutol Optic Neuropathy: Vigilance and Screening, the Keys to Prevent Blindness with the Revised Anti-tuberculous Therapy Regimen</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Saxena, Rohit ; Phuljhele, Swati ; Prakash, Anupam ; Lodha, Rakesh ; Singh, Digvijay ; Karna, Satya ; Mohan, Anant ; Gandhi, Rashmin ; Menon, Vimla ; Garg, Rajiv ; The Inosrg</creator><creatorcontrib>Saxena, Rohit ; Phuljhele, Swati ; Prakash, Anupam ; Lodha, Rakesh ; Singh, Digvijay ; Karna, Satya ; Mohan, Anant ; Gandhi, Rashmin ; Menon, Vimla ; Garg, Rajiv ; The Inosrg</creatorcontrib><description>There has been change in the guidelines for the management of tuberculosis in India. The new guidelines advocate the daily use of Ethambutol for both intensive and continuation phase of the treatment. This may be a matter of concern as increased cumulative dose may lead to increase in incidence of toxic optic neuropathy due to ethambutol. Indian Neuro-Ophthalmology Society has taken cognizance of the issue and has come-up with guidelines for prevention and early detection of the toxic optic neuropathy.</description><identifier>ISSN: 0004-5772</identifier><identifier>PMID: 33527812</identifier><language>eng</language><publisher>India</publisher><subject>Antitubercular Agents - adverse effects ; Blindness ; Ethambutol - adverse effects ; Humans ; India - epidemiology ; Optic Nerve Diseases - chemically induced ; Optic Nerve Diseases - diagnosis ; Optic Nerve Diseases - prevention & control ; Tuberculosis - drug therapy</subject><ispartof>Journal of the Association of Physicians of India, 2021-02, Vol.69 (2), p.54</ispartof><rights>Journal of the Association of Physicians of India 2011.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33527812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saxena, Rohit</creatorcontrib><creatorcontrib>Phuljhele, Swati</creatorcontrib><creatorcontrib>Prakash, Anupam</creatorcontrib><creatorcontrib>Lodha, Rakesh</creatorcontrib><creatorcontrib>Singh, Digvijay</creatorcontrib><creatorcontrib>Karna, Satya</creatorcontrib><creatorcontrib>Mohan, Anant</creatorcontrib><creatorcontrib>Gandhi, Rashmin</creatorcontrib><creatorcontrib>Menon, Vimla</creatorcontrib><creatorcontrib>Garg, Rajiv</creatorcontrib><creatorcontrib>The Inosrg</creatorcontrib><title>Ethambutol Optic Neuropathy: Vigilance and Screening, the Keys to Prevent Blindness with the Revised Anti-tuberculous Therapy Regimen</title><title>Journal of the Association of Physicians of India</title><addtitle>J Assoc Physicians India</addtitle><description>There has been change in the guidelines for the management of tuberculosis in India. The new guidelines advocate the daily use of Ethambutol for both intensive and continuation phase of the treatment. This may be a matter of concern as increased cumulative dose may lead to increase in incidence of toxic optic neuropathy due to ethambutol. Indian Neuro-Ophthalmology Society has taken cognizance of the issue and has come-up with guidelines for prevention and early detection of the toxic optic neuropathy.</description><subject>Antitubercular Agents - adverse effects</subject><subject>Blindness</subject><subject>Ethambutol - adverse effects</subject><subject>Humans</subject><subject>India - epidemiology</subject><subject>Optic Nerve Diseases - chemically induced</subject><subject>Optic Nerve Diseases - diagnosis</subject><subject>Optic Nerve Diseases - prevention & control</subject><subject>Tuberculosis - drug therapy</subject><issn>0004-5772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtOwzAUAL0A0VK4AvIBiOTYcZywK1X5iIoiKGwrf14So8SJbKcoB-DeID6r2YxmMUdoTgjJEi4EnaHTEN4JYSVj9ATNGONUFCmdo891bGSnxti3eDtEq_EjjL4fZGymK_xma9tKpwFLZ_CL9gDOuvoSxwbwA0wBxx4_eTiAi_i6tc44CAF_2Nj8KM9wsAEMXrpokzgq8Hps-zHgXQNeDtO3UNsO3Bk6rmQb4PyPC_R6s96t7pLN9vZ-tdwkQ0rzmBTCMJ2JjJY8NRnTBRGCa8kVpDpnUgMpQGrBWK4oV4LmXJKyzDWrOMhKGbZAF7_dYVQdmP3gbSf9tP__wb4Aqkxdzg</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Saxena, Rohit</creator><creator>Phuljhele, Swati</creator><creator>Prakash, Anupam</creator><creator>Lodha, Rakesh</creator><creator>Singh, Digvijay</creator><creator>Karna, Satya</creator><creator>Mohan, Anant</creator><creator>Gandhi, Rashmin</creator><creator>Menon, Vimla</creator><creator>Garg, Rajiv</creator><creator>The Inosrg</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>202102</creationdate><title>Ethambutol Optic Neuropathy: Vigilance and Screening, the Keys to Prevent Blindness with the Revised Anti-tuberculous Therapy Regimen</title><author>Saxena, Rohit ; Phuljhele, Swati ; Prakash, Anupam ; Lodha, Rakesh ; Singh, Digvijay ; Karna, Satya ; Mohan, Anant ; Gandhi, Rashmin ; Menon, Vimla ; Garg, Rajiv ; The Inosrg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-87d3c4742951d43c80775ca5be1c63ace08eac7336b25b7265a0996c3f5eafbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antitubercular Agents - adverse effects</topic><topic>Blindness</topic><topic>Ethambutol - adverse effects</topic><topic>Humans</topic><topic>India - epidemiology</topic><topic>Optic Nerve Diseases - chemically induced</topic><topic>Optic Nerve Diseases - diagnosis</topic><topic>Optic Nerve Diseases - prevention & control</topic><topic>Tuberculosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saxena, Rohit</creatorcontrib><creatorcontrib>Phuljhele, Swati</creatorcontrib><creatorcontrib>Prakash, Anupam</creatorcontrib><creatorcontrib>Lodha, Rakesh</creatorcontrib><creatorcontrib>Singh, Digvijay</creatorcontrib><creatorcontrib>Karna, Satya</creatorcontrib><creatorcontrib>Mohan, Anant</creatorcontrib><creatorcontrib>Gandhi, Rashmin</creatorcontrib><creatorcontrib>Menon, Vimla</creatorcontrib><creatorcontrib>Garg, Rajiv</creatorcontrib><creatorcontrib>The Inosrg</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of the Association of Physicians of India</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saxena, Rohit</au><au>Phuljhele, Swati</au><au>Prakash, Anupam</au><au>Lodha, Rakesh</au><au>Singh, Digvijay</au><au>Karna, Satya</au><au>Mohan, Anant</au><au>Gandhi, Rashmin</au><au>Menon, Vimla</au><au>Garg, Rajiv</au><au>The Inosrg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ethambutol Optic Neuropathy: Vigilance and Screening, the Keys to Prevent Blindness with the Revised Anti-tuberculous Therapy Regimen</atitle><jtitle>Journal of the Association of Physicians of India</jtitle><addtitle>J Assoc Physicians India</addtitle><date>2021-02</date><risdate>2021</risdate><volume>69</volume><issue>2</issue><spage>54</spage><pages>54-</pages><issn>0004-5772</issn><abstract>There has been change in the guidelines for the management of tuberculosis in India. The new guidelines advocate the daily use of Ethambutol for both intensive and continuation phase of the treatment. This may be a matter of concern as increased cumulative dose may lead to increase in incidence of toxic optic neuropathy due to ethambutol. Indian Neuro-Ophthalmology Society has taken cognizance of the issue and has come-up with guidelines for prevention and early detection of the toxic optic neuropathy.</abstract><cop>India</cop><pmid>33527812</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-5772 |
| ispartof | Journal of the Association of Physicians of India, 2021-02, Vol.69 (2), p.54 |
| issn | 0004-5772 |
| language | eng |
| recordid | cdi_pubmed_primary_33527812 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antitubercular Agents - adverse effects Blindness Ethambutol - adverse effects Humans India - epidemiology Optic Nerve Diseases - chemically induced Optic Nerve Diseases - diagnosis Optic Nerve Diseases - prevention & control Tuberculosis - drug therapy |
| title | Ethambutol Optic Neuropathy: Vigilance and Screening, the Keys to Prevent Blindness with the Revised Anti-tuberculous Therapy Regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T02%3A51%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ethambutol%20Optic%20Neuropathy:%20Vigilance%20and%20Screening,%20the%20Keys%20to%20Prevent%20Blindness%20with%20the%20Revised%20Anti-tuberculous%20Therapy%20Regimen&rft.jtitle=Journal%20of%20the%20Association%20of%20Physicians%20of%20India&rft.au=Saxena,%20Rohit&rft.date=2021-02&rft.volume=69&rft.issue=2&rft.spage=54&rft.pages=54-&rft.issn=0004-5772&rft_id=info:doi/&rft_dat=%3Cpubmed%3E33527812%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33527812&rfr_iscdi=true |